Partnering Spotlight
EnVivo Pharma: “It is going to be a big year for us”
Kees Been, CEO of EnVivo, arrives in Milan for BIO-Europe Spring looking for partners who can help bring his lead CNS products to market. Read more »
partneringNEWS:TV
Venture capital is the most expensive form of capital, so companies are advised to be creative in sourcing other types of funding. With the current capital headwinds, creative alternatives may be the only options companies have. Read more »
The bar is higher than it has ever been for emerging innovators to secure a partnership. Speakers at Tuesday’s plenary luncheon at Biotech Showcase™ 2012 spoke of the realities and substantial challenges of an environment that increasingly incorporates external and internal development programs.
Read more »
While the rest of the world struggles, China is setting new records in venture capital investment, IPO and M&A activity, and partnering deals. Read more »
Regenerative medicine has the power to transform healthcare, incorporating a wide variety of therapies. When incorporated into clinical practice, regenerative therapies may save USD 250 billion per year in the US alone. Read more »
It’s never too early to plan an exit strategy. Panelists at the Biotech Showcase™ 2012 luncheon plenary session Monday all agreed that, although that strategy may include an IPO, exit planning should include other strategies as well. Read more »
Infectious diseases are the number two killer globally, just behind cardiovascular disease. Aside from the scientific challenges, biotech companies conducting infectious disease work are moving from seemingly random approaches to iterative optimizations that deliver candidates on schedule, cost-effectively, said expert panelists at Biotech Showcase™ 2012. Read more »
For many years Harry Glorikian, Managing Director, Scientia Advisors has been helping companies navigate the dynamic, yet increasingly turbulent, life science market. Over the holidays we had the chance to meet with Glorikian to get a peek at what’s in store for several sectors in the healthcare industry in 2012 and beyond. Read more »
The quality of medical treatment is dependent on rapid and accurate diagnosing of the disease, as well as safeguarding the life of the patient. Apart from infectious diseases, most diseases do not have that “tell-all” diagnostic marker that provides an adequate picture of the patient and their particular disease. Seegene, Inc., sees a combination of surrogate markers in a single clinically validated assay as the most effective tool in disease identification, treatment and management, while keeping the patient in focus. Read more »
Hot Companies
Newsletter